Risk of SARS-CoV2-Related Mortality in Non-Small Cell Lung Cancer Patients Treated with First-Line Immunotherapy Alone or in Combination with Chemotherapy.
SARS-CoV-2
immunotherapy
lung cancer
mortality
neutrophil-to-lymphocyte ratio (NLR)
Journal
Cancer investigation
ISSN: 1532-4192
Titre abrégé: Cancer Invest
Pays: England
ID NLM: 8307154
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
pubmed:
20
8
2021
medline:
22
4
2022
entrez:
19
8
2021
Statut:
ppublish
Résumé
The impact of systemic anticancer treatments on SARS-CoV-2-related mortality is still debatable. By a retrospective analysis of patients with non-small-cell lung cancer (NSCLC) treated with first-line Pembrolizumab or in combination with chemotherapy (ChT) during the first surge of the pandemic. The adjusted risk of death was higher in patients treated with ChT + Pembrolizumab (HR 4.6, 1.2-17.4, The addition of ChT to immunotherapy could be associated with increased risk of mortality and higher SARS-CoV-2-related mortality rate.
Sections du résumé
BACKGROUND
BACKGROUND
The impact of systemic anticancer treatments on SARS-CoV-2-related mortality is still debatable.
METHODS
METHODS
By a retrospective analysis of patients with non-small-cell lung cancer (NSCLC) treated with first-line Pembrolizumab or in combination with chemotherapy (ChT) during the first surge of the pandemic.
RESULTS
RESULTS
The adjusted risk of death was higher in patients treated with ChT + Pembrolizumab (HR 4.6, 1.2-17.4,
CONCLUSIONS
CONCLUSIONS
The addition of ChT to immunotherapy could be associated with increased risk of mortality and higher SARS-CoV-2-related mortality rate.
Identifiants
pubmed: 34409906
doi: 10.1080/07357907.2021.1970761
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM